TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

NCT02927964 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Grade 1 Follicular Lymphoma
Grade 2 Follicular Lymphoma
Grade 3a Follicular Lymphoma
Recurrent Follicular Lymphoma
Refractory Follicular Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma

Interventions

DRUG: Ibrutinib
RADIATION: Radiation Therapy
DRUG: TLR9 Agonist SD-101

Sponsor

Robert Lowsky

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]